Seattle Genetics - 48 Year Dividend History | SGEN

Historical dividend payout and yield for Seattle Genetics (SGEN) since 1971. The current TTM dividend payout for Seattle Genetics (SGEN) as of June 17, 2019 is $0.00. The current dividend yield for Seattle Genetics as of June 17, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.050B $0.655B
Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, ADCETRIS? (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $107.397B 12.14
Gilead Sciences (GILD) United States $84.602B 10.27
Bio-Techne Corp (TECH) United States $7.890B 53.83